Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-138810

Published: 2020

Journal Articles

RUNX1 Mutations Lead to a Myeloid Differentiation Block in Association with Enhanced Proliferation By Altering the RUNX1 Transcriptional Program

Mylène Gerritsen, MSc, Esther Tijchon, PhD, Guoqiang Yi, PhD, Jorren Kuster, BSc, Jan Jacob Schuringa, PhD, Joost H.A. Martens, Edo Vellenga, MD

Blood (2017) 130 (Supplement 1): 1229.

https://doi.org/10.1182/blood.V130.Suppl_1.1229.1229

Published: 2017

Journal Articles

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Blood (2017) 130 (Supplement 1): 2016.

https://doi.org/10.1182/blood.V130.Suppl_1.2016.2016

Published: 2017

Journal Articles

Putative Autophagy Protein VMP1 Amplifies Protective Autophagy Under Stress Conditions in AML Cells

Hendrik Folkerts, MSc, Albertus T.J. Wierenga, PhD, Jan Jacob Schuringa, PhD, Edo Vellenga, MD

Blood (2017) 130 (Supplement 1): 3918.

https://doi.org/10.1182/blood.V130.Suppl_1.3918.3918

Published: 2017

Journal Articles

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

Geert Huls, MD PhD, Dana Chitu, Violaine Havelange, Mojca Jongen-Lavrencic, MD PhD, Arjen van de Loosdrecht, Bart J. Biemond, MD PhD, Harm Sinnege, MDPhD, Beata Hodossy, Carlos Graux, Marinus van Marwijk Kooij, MD PhD, Okke de Weerdt, MD, Dimitri Breems, MD PhD, Saskia Klein, MD, Jurgen Kuball, MD, Gert J. Ossenkoppele, MD PhD, Bob Lowenberg, MD PhD, Edo Vellenga, MD

Blood (2017) 130 (Supplement 1): 463.

https://doi.org/10.1182/blood.V130.Suppl_1.463.463

Published: 2017

Journal Articles

Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial

Ruth Wester, Bronno van der Holt, Emelie Asselbergs, Sonja Zweegman, MD PhD, Marie José Kersten, MD, Edo Vellenga, MD, Marinus van Marwijk Kooij, MD PhD, Okke de Weerdt, MD, Monique C Minnema, Sarah Lonergan, Antonio Palumbo, MD, Henk M Lokhorst, Annemiek Broyl, MD PhD, Karim Saad Iskander, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 3141.

https://doi.org/10.1182/blood.V130.Suppl_1.3141.3141

Published: 2017

Journal Articles

Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)

Pierre Fenaux, MD PhD, Azra Raza, MD, Edo Vellenga, MD, Uwe Platzbecker, MD, Valeria Santini, MD, Irina Samarina, MD, Koen Van Eygen, MD, Maria Díez-Campelo, MD PhD, Mrinal M. Patnaik, MDMBBS, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Aleksandra Rizo, MD PhD, David P. Steensma, MD

Blood (2017) 130 (Supplement 1): 4256.

https://doi.org/10.1182/blood.V130.Suppl_1.4256.4256

Published: 2017

Journal Articles

CITED2 Affects Leukemic Cell Survival By Interfering with p53 Activation

Katharina Mattes, MSc, Gerbrig Berger, BSc, Marjan Geugien, MSc, Joost H.A. Martens, Edo Vellenga, MD PhD, Hein Schepers, PhD

Blood (2016) 128 (22): 1542.

https://doi.org/10.1182/blood.V128.22.1542.1542

Published: 2016

Journal Articles

Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT

Blood (2016) 128 (22): 3467.

https://doi.org/10.1182/blood.V128.22.3467.3467

Published: 2016

Journal Articles

Following Autologous Stem Cell Transplantation (1 Yr) Mesenchymal Stem Cells Are Functionally Impaired with Reduced Hematopoietic Support

Catharina Hazenberg, MD, Fiona A.J. van den Heuvel, Edo Vellenga, MD PhD, Annet Z. Brouwers-Vos, Gerbrig Berger, BSc, Jan Jacob Schuringa, PhD

Blood (2016) 128 (22): 3888.

https://doi.org/10.1182/blood.V128.22.3888.3888

Published: 2016

Journal Articles

RUNX1 Mutations Cause a Myeloid Differentiation Block Leading to the Formation of a Long Term Expanding CD34 + /CD33 + /CD45RA + /CD123 + Cell Population

Myléne Gerritsen, MSc, Esther Tijchon, PhD, Amit Mandoli, PhD, Joost H.A. Martens, Jan Jacob Schuringa, PhD, Edo Vellenga, MD PhD

Blood (2016) 128 (22): 1979.

https://doi.org/10.1182/blood.V128.22.1979.1979

Published: 2016

Journal Articles

Lenalidomide with or without Erythropoietin and Granulocyte-Colony Stimulating Factor Shows Efficacy in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndrome with or without Del 5q, Refractory or Unlikely to Respond to Erythropoietin. Results of a HOVON89 Phase II Randomized Multicenter Study. (EudraCT 2008-002195-10)

Blood (2016) 128 (22): 224.

https://doi.org/10.1182/blood.V128.22.224.224

Published: 2016

Journal Articles

Blocking the Autophagy Pathway As Potential Target for the Treatment of Wild Type P53 AMLs

Hendrik Folkerts, MSc, Susan Hilgendorf, MSc, Albertus T. Wierenga, PhD, Paul J. Coffer, PhD, Jan Jacob Schuringa, PhD, Edo Vellenga, MD PhD

Blood (2016) 128 (22): 770.

https://doi.org/10.1182/blood.V128.22.770.770

Published: 2016

Journal Articles

Targeting Autophagy As a Potential Therapeutic Strategy for the Treatment of AML

Hendrik Folkerts, MSc, Bart-Jan A.T.J. Wierenga, PhD, Paul J. Coffer, PhD, Jan Jacob Schuringa, PhD, Edo Vellenga, MD PhD

Blood (2015) 126 (23): 3831.

https://doi.org/10.1182/blood.V126.23.3831.3831

Published: 2015

Journal Articles

CITED2 Cooperates with Low PU.1 and DNMT3A to Maintain Self-Renewal in Hematopoietic Stem Cells

Hein Schepers, PhD, Patrick Korthuis, MSc, Marjan Geugien, MSc, Jennifer Jaques, MSc, Tihomira I. Todorova, MSc, Ulrich Steidl, MD PhD, Jan Jacob Schuringa, PhD, Edo Vellenga, MD PhD

Blood (2015) 126 (23): 309.

https://doi.org/10.1182/blood.V126.23.309.309

Published: 2015

Journal Articles

Loss of ASXL1 Triggers an Apoptotic Response in Human Hematopoietic Stem and Progenitor Cells

Susan Hilgendorf, MSc, Hendrik Folkerts, MSc, Jan Jacob Schuringa, PhD, Edo Vellenga, MD PhD

Blood (2015) 126 (23): 4107.

https://doi.org/10.1182/blood.V126.23.4107.4107

Published: 2015

Journal Articles

Loss of ASXL1 Triggers an Apoptotic Response in Human Hematopoetic Stem and Progenitor Cells

Susan Hilgendorf, Hendrik Folkerts, Jan Jacob Schuringa, PhD, Edo Vellenga, MD PhD

Blood (2014) 124 (21): 4619.

https://doi.org/10.1182/blood.V124.21.4619.4619

Published: 2014

Journal Articles

Combined Treatment of Bortezomib, Continuous Low-Dose Cyclophosphamide and Dexamethasone Followed By One Year of Maintenance Treatment for Refractory or Relapsed Multiple Myeloma Patients: A Prospective Phase II Study

Esther GM Waal de, MD, Linda Munck de, Gerhard Woolthuis, MD, Annet velden Van Der, MD, Yvonne Tromp, MD, Mels Hoogendoorn, MD PhD, Edo Vellenga, MD PhD, Sjoerd Hovenga, MDPhD

Blood (2014) 124 (21): 4733.

https://doi.org/10.1182/blood.V124.21.4733.4733

Published: 2014

Journal Articles

ATG5 and ATG7 Fulfill Essential and Non-Redundant Roles in Human Hematopoietic Stem/Progenitor Cells

Hendrik Folkerts, Maria Catalina Gomez Puerto, Albertus T.J. Wierenga, PhD, Koen Schepers, PhD, Jan Jacob Schuringa, PhD, Paul J. Coffer, PhD BA, Edo Vellenga, MD PhD

Blood (2014) 124 (21): 4316.

https://doi.org/10.1182/blood.V124.21.4316.4316

Published: 2014

Journal Articles

Mesenchymal Stem Cells from Patients 1 Year Following Autologous Stem Cell Transplantation Have a Pro-Inflammatory and Senescent Phenotype Compromising the Support of Hematopoietic Stem Cells

Carin L.E. Hazenberg, MD, Fiona A.J. van den Heuvel, Ben N.G. Giepmans, PhD, Jan Jacob Schuringa, PhD, Edo Vellenga, MD PhD

Blood (2014) 124 (21): 4368.

https://doi.org/10.1182/blood.V124.21.4368.4368

Published: 2014

NARROW

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

RUNX1 Mutations Lead to a Myeloid Differentiation Block in Association with Enhanced Proliferation By Altering the RUNX1 Transcriptional Program

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Putative Autophagy Protein VMP1 Amplifies Protective Autophagy Under Stress Conditions in AML Cells

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial

Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)

CITED2 Affects Leukemic Cell Survival By Interfering with p53 Activation

Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT

Following Autologous Stem Cell Transplantation (1 Yr) Mesenchymal Stem Cells Are Functionally Impaired with Reduced Hematopoietic Support

RUNX1 Mutations Cause a Myeloid Differentiation Block Leading to the Formation of a Long Term Expanding CD34 + /CD33 + /CD45RA + /CD123 + Cell Population

Blocking the Autophagy Pathway As Potential Target for the Treatment of Wild Type P53 AMLs

Targeting Autophagy As a Potential Therapeutic Strategy for the Treatment of AML

CITED2 Cooperates with Low PU.1 and DNMT3A to Maintain Self-Renewal in Hematopoietic Stem Cells

Loss of ASXL1 Triggers an Apoptotic Response in Human Hematopoietic Stem and Progenitor Cells

Loss of ASXL1 Triggers an Apoptotic Response in Human Hematopoetic Stem and Progenitor Cells

Combined Treatment of Bortezomib, Continuous Low-Dose Cyclophosphamide and Dexamethasone Followed By One Year of Maintenance Treatment for Refractory or Relapsed Multiple Myeloma Patients: A Prospective Phase II Study

ATG5 and ATG7 Fulfill Essential and Non-Redundant Roles in Human Hematopoietic Stem/Progenitor Cells

Mesenchymal Stem Cells from Patients 1 Year Following Autologous Stem Cell Transplantation Have a Pro-Inflammatory and Senescent Phenotype Compromising the Support of Hematopoietic Stem Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only